Needle

Liquid Biopsy Market size is set to grow by USD 1.74 billion from 2021 to 2026 | The Increasing incidence of cancer drives the market growth - Technavio

Retrieved on: 
火曜日, 10月 24, 2023
Neoplasm, OME Care, Laboratory, Abdominal ultrasonography, Incidence, Liquid biopsy, Johns Hopkins University, RNA, Biotechnology, GRAIL, ROW, Prevalence, Disease, Developed country, Chinese, R, Helmy Eltoukhy, World Games, Growth, Life expectancy, Methylation, Risk, Exosome, Cancer, Biopsy, Hospital, Breast cancer, Geisinger Health System, USD, Needle, Patient, Diagnosis, Bias, CTC, DNA, Medical imaging, Geography, COVID-19

NEW YORK, Oct. 24, 2023 /PRNewswire/ -- The liquid biopsy market size is estimated to grow by USD 1.74 billion from 2021 to 2026, according to Technavio.

Key Points: 
  • NEW YORK, Oct. 24, 2023 /PRNewswire/ -- The liquid biopsy market size is estimated to grow by USD 1.74 billion from 2021 to 2026, according to Technavio.
  • The growing incidence of cancers will subsequently increase the diagnosis using the liquid biopsy method, expected to drive the market growth during the forecast period.
  • The increasing funding/investment for fluid biopsy is a liquid biopsy market trend that is expected to drive market growth.
  • Growth of the liquid biopsy market across North America, Europe, Asia, and ROW
    Gain instant access to 17,000+ market research reports.

Global Syringes & Needles Market Soars with a Strong 7.93% CAGR, Expected to Reach $47.20 Billion by 2029 - ResearchAndMarkets.com

Retrieved on: 
金曜日, 10月 20, 2023
Medical Supplies, Health, Ageing, Cardinal Health, Prevalence, Conditional sentence, Diabetes, BD, Syringe, Injury, Growth, Hospital, Needle, Beauty salon, Dentistry

The global syringes & needles market is experiencing robust growth, with a projected CAGR of 7.93% from 2023 to 2029.

Key Points: 
  • The global syringes & needles market is experiencing robust growth, with a projected CAGR of 7.93% from 2023 to 2029.
  • The market, valued at $29.85 billion in 2023, is expected to reach $47.20 billion by 2029.
  • Several key factors are driving this growth, while the market is also influenced by regional dynamics and market segmentation.
  • Leading players dominating the global syringes & needles market include BD, Cardinal Health, B Braun, Nipro, and Terumo Corp.

Vaccine Journal Highlights the Potential for Self-Administration of Vaccines Using Vaxxas High-Density Microarray Patch (HD-MAP)

Retrieved on: 
木曜日, 10月 19, 2023
Biotechnology, Medical Devices, Infectious Diseases, Health, Pharmaceutical, Lymph, Measles, Skin, Personal protective equipment, Fever Dream, Vaccination, Immune system, COVID-19, Pharmacy, Evaluation, Biodegradable waste, Rubella, Public, Needle, Cancer, Syringe, Pharmaceutical industry, Vaccine

The publication outlines the potential for Vaxxas’ HD-MAP to enhance vaccine performance as well as increasing rates and acceptance of vaccination based on needle-free self-administration.

Key Points: 
  • The publication outlines the potential for Vaxxas’ HD-MAP to enhance vaccine performance as well as increasing rates and acceptance of vaccination based on needle-free self-administration.
  • The HD-MAP, upon which vaccines are ‘printed’ and dried, also provides storage and distribution benefits due to reduced cold chain requirements generally associated with vaccines delivered by needle and syringe.
  • Vaxxas is advancing a robust pipeline of pre-clinical and clinical stage HD-MAP vaccine candidates and has recently concluded multiple Phase I clinical studies.
  • The current Vaxxas pipeline targets COVID-19, seasonal and pandemic influenza, typhoid, measles and rubella, and cancer.

United States Cardiovascular Needle Market Insights and Forecast Report, 2022-2023 & 2026 - AI is Making Inroads in Cardiovascular Medicine, Improving Prognosis and Treatment Outcomes - ResearchAndMarkets.com

Retrieved on: 
火曜日, 10月 17, 2023
Health, Cardiology, Diagnosis, Cardiovascular disease, Nursing care plan, Infection, COVID-19, Disease, Injury, Becton, Dickinson and Company headquarters, Bleeding, Brain, Prevalence, Blunt cardiac injury, Artificial intelligence, AI, Risk, Heart, Mortality, Becton, Splenic infarction, Medtronic, BD, Type, Gesellschaft mit beschränkter Haftung, CVD, Society, Blood, Johns Hopkins, Growth, Surgical suture, ICU, Disorder, Tissue, Hospital, FSSB, Skin, Stroke, Needle, Prognosis, Birth, Patient, Surgeon, Fatality, Beauty salon, Pharmaceutical industry, Medical device, Silk

The US cardiovascular needle market is foreseen to reach US$36.71 million in 2023, growing at a CAGR of 7.55% during the forecasted period.

Key Points: 
  • The US cardiovascular needle market is foreseen to reach US$36.71 million in 2023, growing at a CAGR of 7.55% during the forecasted period.
  • The treatment of these disorders often requires specialized surgeries, during which cardiovascular needles are used to suture the wounds.
  • Consequently, the increasing prevalence of cardiovascular diseases has driven the demand for cardiovascular devices for diagnosis and treatment, contributing to the growth of the cardiovascular needle market in recent years.
  • Artificial intelligence (AI) is making inroads in cardiovascular medicine, improving prognosis and treatment outcomes.

BD, Casella Complete Industry-First Pilot Recycling 40,000 Pounds of Used Medical Devices

Retrieved on: 
月曜日, 10月 16, 2023
Health, Hospital, BDX, Recycling, NYSE, Becton, Dickinson and Company headquarters, ESG, Casella Waste Systems, Municipal solid waste, State, Becton, BD, Syringe, Medical device, Biodegradable waste, Needle, Plastic, Casella

FRANKLIN LAKES, N.J. and RUTLAND, Vt., Oct. 16, 2023 (GLOBE NEWSWIRE) -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Casella Waste Systems, Inc. (Nasdaq: CWST) (Casella), a solid waste, recycling, and resource management services company, today announced the most recent results of a recycling pilot to manage discarded syringes and needles that led to 40,000 pounds of medical waste being recycled and diverted from disposal.

Key Points: 
  • The medical waste was collected across a variety of health care facilities and all of the plastics were diverted from disposal and recycled.
  • The pilot also assessed technical feasibility of two types of technology – mechanical and advanced recycling – both showing favorable results in their ability to successfully recycle used medical devices for use in other products.
  • The teams will also increase focus to cover other types of medical materials for recycling, as well as reclaiming the used devices and returning them to the manufacturing process.
  • “This pilot showcases the strength of collaborative partnerships when it comes to sustainable material management practices,” said Casella Chairman and CEO, John W. Casella.

Cleanfarms is Collecting Unwanted Agricultural Pesticides and Old Livestock/Equine Medications in South Saskatchewan this Fall

Retrieved on: 
木曜日, 10月 12, 2023
Needle, Partnership, Farm, Davidson, DIN, Nitric acid, Moose Jaw, Livestock, Intersection, Farmer, Goat, AG, Maple Creek, Cattle, Raymore, Collection, NOT, Parrish & Heimbecker, Crop protection, McRorie, Formaldehyde, Pest Control Products Act, Cargill, Coronach, Genesis, Grenfell, Poultry, Pest control, MOOSE, Aerosol, Weyburn, Eston, Horse, Old High St Stephen's, Pesticide, Agriculture, Potash, Payment card, Nightclub, Renewable energy, Reinsurance, JAW, Central Butte

MOOSE JAW, Saskatchewan, Oct. 12, 2023 (GLOBE NEWSWIRE) -- This fall, farmers in Saskatchewan south of Davidson can safely dispose of unwanted agricultural pesticides and old, obsolete livestock and equine medications through a Cleanfarms program.

Key Points: 
  • MOOSE JAW, Saskatchewan, Oct. 12, 2023 (GLOBE NEWSWIRE) -- This fall, farmers in Saskatchewan south of Davidson can safely dispose of unwanted agricultural pesticides and old, obsolete livestock and equine medications through a Cleanfarms program.
  • 10, 306-331-5706
    Balgonie – October 24 – Nutrien Ag Solutions, 228 Old Hwy., 306-771-2032
    Central Butte – October 24 – Hawks Agro, South Hwy.
  • Materials accepted in the Cleanfarms program include:
    Unwanted (or “obsolete”) agricultural pesticides (identified with a Pest Control Product number on the label.
  • Next fall (2024), events will operate in Northern Saskatchewan and return to the southern region in 2026.

FDA Awards HistoSonics Clearance of its First-of-a-Kind Edison® Histotripsy System

Retrieved on: 
月曜日, 10月 9, 2023
Surgery, Medical Devices, FDA, Clinical Trials, Health Technology, Biotechnology, Radiology, Health, Oncology, Congress, Infection, Food, Hepatocellular carcinoma, Blue, Breast, Rectum, Liver disease, Liver, Radiation, Safety, University, CTCAE, Patient, Education, High-intensity focused ultrasound, Thomas Edison, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Amaral, Colon, Science, Neoplasm, Needle, HCC, Physician, Medical imaging

Marketing authorization makes Edison the first and only histotripsy platform available in the Unites States.

Key Points: 
  • Marketing authorization makes Edison the first and only histotripsy platform available in the Unites States.
  • View the full release here: https://www.businesswire.com/news/home/20231009669222/en/
    HistoSonics Edison Histotripsy System (Photo: Business Wire)
    FDA authorization was based, in part, on data from the #HOPE4LIVER Trials in 13 trial sites across the US and Europe.
  • HistoSonics' Edison System uses proprietary technology and advanced imaging to deliver personalized, non-invasive histotripsy treatments with precision and control.
  • The Edison System is indicated for the non-invasive destruction of liver tumors, including unresectable liver tumors, using a non-thermal, mechanical process of focused ultrasound.

BD, Casella Complete Industry-First Pilot Recycling 40,000 Pounds of Used Medical Devices

Retrieved on: 
月曜日, 10月 16, 2023
Needle, Health, Hospital, BDX, Recycling, NYSE, Becton, Dickinson and Company headquarters, ESG, Casella Waste Systems, Municipal solid waste, State, Becton, BD, Syringe, Medical device, Biodegradable waste, Plastic, Casella

FRANKLIN LAKES, N.J. and RUTLAND, Vt., Oct. 16, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Casella Waste Systems, Inc. (Nasdaq: CWST) (Casella), a solid waste, recycling, and resource management services company, today announced the most recent results of a recycling pilot to manage discarded syringes and needles that led to 40,000 pounds of medical waste being recycled and diverted from disposal.  

Key Points: 
  • These containers included a broad range of medical equipment and materials, primarily syringes and needles.
  • The pilot also assessed technical feasibility of two types of technology – mechanical and advanced recycling – both showing favorable results in their ability to successfully recycle used medical devices for use in other products.
  • The teams will also increase focus to cover other types of medical materials for recycling, as well as reclaiming the used devices and returning them to the manufacturing process.
  • "This pilot showcases the strength of collaborative partnerships when it comes to sustainable material management practices," said Casella Chairman and CEO, John W. Casella.

Aware Unveils Industry’s Most Accurate Risk Assessment Calculator to Secure Enterprises

Retrieved on: 
木曜日, 10月 5, 2023
Software, Banking, Professional Services, Data Management, Technology, Artificial Intelligence, Security, Legal, Insurance, Human Resources, Finance, Consulting, Benchmark, Microsoft, Workplace, Cisco, Intelligence, WorkJam, GDPR, Organization, Bullying, Risk, Culture, Communication, Intellectual property, PCI, Toxicity, Heart, Data management, Meta, GRC, CV, Workflow, PII, Ecosystem, Natural language processing, Experience management, NLP, Cisco Webex, Zoom, PHI, Needle, Privacy, Nature, Research, Mobile phone, Audit, Risk management, Computer security, Slack

Aware, the AI Data Platform for helping enterprises unify collaboration governance, risk, and compliance (GRC), today announced the industry’s most accurate Risk Assessment Calculator.

Key Points: 
  • Aware, the AI Data Platform for helping enterprises unify collaboration governance, risk, and compliance (GRC), today announced the industry’s most accurate Risk Assessment Calculator.
  • The calculator is the latest application designed by Aware to help organizations bolster their risk and compliance posture.
  • The data cited in Aware’s Risk Assessment Calculator is backed by the 2023 Risk Awareness Benchmark report.
  • Click here to receive your free risk assessment and discover how Aware can help you safeguard your company’s most important data.

Altaviz Unveils Gas-Powered Auto-Injector Platform for High Viscosity and High-Volume Biologics Drug Delivery

Retrieved on: 
金曜日, 10月 13, 2023
PDA, Auld, Therapy, Platform, Temperature, Environment, Needle, Patient, Medical device, Pharmaceutical industry

The arrival of the AltaVISC Auto-injector Platform ushers in a realm of new possibilities for the delivery of high viscosity, high-volume biologics with exceptional simplicity and comfortable patient experience.

Key Points: 
  • The arrival of the AltaVISC Auto-injector Platform ushers in a realm of new possibilities for the delivery of high viscosity, high-volume biologics with exceptional simplicity and comfortable patient experience.
  • "To put things succinctly, the AltaVISC Platform is simply better than everything else in the market right now," says Jack Auld, Co-CEO at Altaviz.
  • "A viable, patient-centric solution for the delivery of next-gen therapies has been, not just elusive, but non-existent until now.
  • The article, entitled,
    Gas-Powered Autoinjector Platform Enables Biologics Drug Delivery, highlights the following benefits over legacy spring-powered autoinjectors:
    Increased capacity enabled by Pico-Cylinders to deliver high viscosities, smaller needles and large dose volumes.